EcoDrugPlus

Serum Amyloid P-Component

Ensembl ID : ENSOKIG00005015915
Gene Symbol: LOC109899601
2 Cross references
518 Possible Orthologues:

Serum Amyloid P-Component

Ensembl ID : ENSOKIG00005003700
Gene Symbol: LOC109899641
2 Cross references
353 Possible Orthologues:

Si:dkey-211g8.7

Ensembl ID : ENSOKIG00005018837
Gene Symbol: SI:DKEY-211G8.7
1 Cross references
273 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSOKIG00005026234
Gene Symbol: SIRT1
3 Cross references
152 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSOKIG00005048598
Gene Symbol: SMO
3 Cross references
203 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSOKIG00005038468
Gene Symbol: SMO
3 Cross references
203 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSOKIG00005013325
Gene Symbol: LOC109909635
3 Cross references
259 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSOKIG00005050235
Gene Symbol: SCN5LAB
1 Cross references
258 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSOKIG00005003176
Gene Symbol: SCN4A
1 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSOKIG00005012123
Gene Symbol: SCN4A
1 Cross references
192 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSOKIG00005017970
Gene Symbol: SCN8A
1 Cross references
209 Possible Orthologues:

Sodium- And Chloride-Dependent Gaba Transporter 1

Ensembl ID : ENSOKIG00005007368
Gene Symbol: LOC109907771
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).